Literature DB >> 2572003

Acute and subchronic effects of methylenedioxymethamphetamine [(+/-)MDMA] on locomotion and serotonin syndrome behavior in the rat.

L J Spanos1, B K Yamamoto.   

Abstract

Specific behaviors comprising the serotonin syndrome (low body posture, forepaw treading, headweaving) and the autonomic signs of piloerection and salivation were determined and analyzed with locomotor activity in response to MDMA at three doses (2.5, 5.0, and 7.5 mg/kg). All behaviors were dose-responsive. Serotonin syndrome behaviors increased in both intensity and duration of response with increasing doses. In contrast, locomotion varied only in intensity. Subchronic injections, in the same group of animals, permitted an analysis of acute vs. subchronic effects on these same behaviors. Both the serotonin syndrome and locomotor behaviors were augmented on subsequent testing, indicating that, (+/-)MDMA, like amphetamine, is capable of producing behavioral sensitization.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2572003     DOI: 10.1016/0091-3057(89)90044-0

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  48 in total

1.  The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue.

Authors:  Michael H Baumann; Mario A Ayestas; John S Partilla; Jacqueline R Sink; Alexander T Shulgin; Paul F Daley; Simon D Brandt; Richard B Rothman; Arnold E Ruoho; Nicholas V Cozzi
Journal:  Neuropsychopharmacology       Date:  2011-12-14       Impact factor: 7.853

2.  Initial deficit and recovery of function after MDMA preexposure in rats.

Authors:  K A Brennan; S Schenk
Journal:  Psychopharmacology (Berl)       Date:  2005-12-16       Impact factor: 4.530

Review 3.  A developmental comparison of the neurobehavioral effects of ecstasy (MDMA).

Authors:  Brian J Piper
Journal:  Neurotoxicol Teratol       Date:  2006-10-20       Impact factor: 3.763

4.  Repeated MDMA administration increases MDMA-produced locomotor activity and facilitates the acquisition of MDMA self-administration: role of dopamine D2 receptor mechanisms.

Authors:  Ross van de Wetering; Susan Schenk
Journal:  Psychopharmacology (Berl)       Date:  2017-02-10       Impact factor: 4.530

Review 5.  Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine.

Authors:  Lee E Dunlap; Anne M Andrews; David E Olson
Journal:  ACS Chem Neurosci       Date:  2018-07-12       Impact factor: 4.418

Review 6.  Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function.

Authors:  M Isabel Colado; Esther O'Shea; A Richard Green
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

7.  Studies on the role of dopamine D1 receptors in the development and expression of MDMA-induced behavioral sensitization in rats.

Authors:  María Ramos; Beatriz Goñi-Allo; Norberto Aguirre
Journal:  Psychopharmacology (Berl)       Date:  2004-08-27       Impact factor: 4.530

8.  Comparative behavioural and neurochemical studies with a psychomotor stimulant, an hallucinogen and 3,4-methylenedioxy analogues of amphetamine.

Authors:  K M Hegadoren; M T Martin-Iverson; G B Baker
Journal:  Psychopharmacology (Berl)       Date:  1995-04       Impact factor: 4.530

9.  Behavioral, neurochemical and pharmaco-EEG profiles of the psychedelic drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rats.

Authors:  Tomáš Páleníček; Michaela Fujáková; Martin Brunovský; Jiří Horáček; Ingmar Gorman; Marie Balíková; Lukáš Rambousek; Kamila Syslová; Petr Kačer; Petr Zach; Věra Bubeníková-Valešová; Filip Tylš; Anna Kubešová; Jana Puskarčíková; Cyril Höschl
Journal:  Psychopharmacology (Berl)       Date:  2012-07-29       Impact factor: 4.530

10.  Effects of fentanyl on serotonin syndrome-like behaviors in rats.

Authors:  Sonoe Kitamura; Takashi Kawano; Satomi Kaminaga; Daiki Yamanaka; Hiroki Tateiwa; Fabricio M Locatelli; Masataka Yokoyama
Journal:  J Anesth       Date:  2015-10-26       Impact factor: 2.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.